Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 7Solid Tumor 1Ovarian Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Breast Neoplasm Female 1Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed 1

Interventions

Injections 4apatinib 3Cisplatin 3Capecitabine 3toripalimab 2alpha-Synuclein 2Oxaliplatin 2Gemcitabine 2Drug Therapy 2Docetaxel 2trametinib 1tislelizumab 1tesetaxel 1surufatinib 1spartalizumab 1pyrotinib 1pemigatinib 1pembrolizumab 1nimotuzumab 1mogamulizumab 1irinotecan sucrosofate 1fludarabine 1famitinib 1dalpiciclib 1camrelizumab 1YM753 compound 1Vemurafenib 1Taxes 1SHR-1701 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Solid Tumor × dalpiciclib × Clear all
NCT05512780 2022-08-23

Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage â…¡-â…¢ HR-positive/HER2-negative Breast Cancer

Hebei Medical University Fourth Hospital

Phase 2 Unknown
30 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡